UGT1A4多态性与Giredestrant暴露的临床相关变化无关
Vikram Malhi1, Malgorzata Nowicka2, Ya-Chi Chen1
1Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, 650-484-6516, USA.
Cancer chemotherapy and pharmacology
|February 2, 2024
概括
在ER阳性乳腺癌患者中,UGT1A4遗传变异不会显著影响giredestrant的暴露. 这一发现支持giredestrant的持续剂量,无论UGT1A4多态态状态如何.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 在瘤学瘤学.
背景情况:
- 吉雷德斯特兰是ER阳性乳腺癌的口服选择性雌激素受体对抗剂和降解剂 (SERD).
- 在体外研究中,UGT1A4被确定为代谢giredestrant的主要酶.
研究的目的:
- 为了评估UGT1A4基因变异对giredestrant暴露的临床影响.
- 为了确定UGT1A4多态性是否影响giredestrant的药理动力学.
主要方法:
- 从两项临床试验 (GO39932和acelERA乳腺癌) 的179名患者中收集了基因型和药理动力学数据.
- 分析包括对UGT1A4*2和UGT1A4*3等位基频率的评估和单位基分析.
主要成果:
- 对于UGT1A4*2和UGT1A4*3的基因频率分别为3.3%和11%.
- 在野生型UGT1A4患者和UGT1A4*2或*3多态的患者中,Giredestrant的暴露保持一致.
- 在其他UGT1A4变体和化剂暴露之间没有发现显著的关联.
结论:
- UGT1A4多态态状态不太可能是影响giredestrant暴露的临床相关因素.
- 吉雷德斯特兰可以在一个一致的剂量水平上使用,无论患者的UGT1A4多态态状态如何.
相关概念视频
Phase II Reactions: Glucuronidation
428
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
428
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
138
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
138
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Factors Affecting Drug Biotransformation: Biological
153
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
153
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
260
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
260


